Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus

The Cochrane Database of Systematic Reviews
Bianca HemmingsenJørn Wetterslev

Abstract

Patients with type 2 diabetes mellitus (T2D) exhibit an increased risk of cardiovascular disease and mortality compared to the background population. Observational studies report a relationship between reduced blood glucose and reduced risk of both micro- and macrovascular complications in patients with T2D. To assess the effects of targeting intensive versus conventional glycaemic control in T2D patients. Trials were obtained from searches of CENTRAL (The Cochrane Library), MEDLINE, EMBASE, Science Citation Index Expanded, LILACS, and CINAHL (until December 2010). We included randomised clinical trials that prespecified different targets of glycaemic control in adults with T2D. Two authors independently assessed the risk of bias and extracted data. Dichotomous outcomes were assessed by risk ratios (RR) and 95% confidence intervals (CI). Twenty trials randomised 16,106 T2D participants to intensive control and 13,880 T2D participants to conventional glycaemic control. The mean age of the participants was 62.1 years. The duration of the intervention ranged from three days to 12.5 years. The number of participants in the included trials ranged from 20 to 11,140. There was no significant difference between targeting intensive and ...Continue Reading

Citations

Dec 5, 2012·ISRN Endocrinology·Edoardo Mannucci
Jan 1, 2014·Journal of Clinical Medicine·Jing PanKenneth M Baker
May 29, 2013·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Clifford J BaileyUNKNOWN Global Partnership for Effective Diabetes Management
Jun 3, 2017·World Journal of Diabetes·Richard J MacIsaacElif I Ekinci
Jan 14, 2016·The Cochrane Database of Systematic Reviews·Malindu E FernandoJonathan Golledge
Jul 31, 2014·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Tomas HajekMartin Alda
Apr 30, 2014·The Cochrane Database of Systematic Reviews·Rebecca RyanMichael Taylor
Dec 18, 2018·Frontiers in Cardiovascular Medicine·Devinder S DhindsaMichael D Shapiro
May 4, 2017·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Lawrence BlondeUNKNOWN Global Partnership for Effective Diabetes Management
Nov 27, 2020·Frontiers in Immunology·John V ForresterMirela Delibegovic
Mar 25, 2021·Seminars in Vascular Surgery·Rebecca Sorber, Christopher J Abularrage
Aug 2, 2020·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Ioannis IliasThomas Makris
Aug 7, 2021·Diabetes & Metabolism Journal·Catherine Kim
Apr 8, 2019·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Rajaram Krishnasamy, Sureshkumar Periyasamy

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.